Modelling SARS-CoV-2 Infection Using iPSCs & Organoids
Rabbit Polyclonal Anti-SARS-CoV-2 Antibody used in Fig 2 is available from AMSBIO. Speaker Profile: Dr. Kazuo Takayama is a junior associate professor (PI) at Center for iPS cell Research and Application (CiRA), Kyoto University. He started his laboratory at CiRA in March 2020, coinciding with the COVID-19 pandemic. He is developing differentiation technology of airway organoids for COVID-19 research. He is also using iPS cell panels to recapitulate individual differences in the symptoms of COVID-19. In this seminar, he will introduce the latest findings and challenges of COVID-19 research utilizing organoids and iPS cells.
Further reading of interest:
1. Suzuki, T., Ito, Y., Sakai, Y., Saito, A., Okuzaki, D., Motooka, D., … & Takayama, K. (2020). Generation of human bronchial organoids for SARS-CoV-2 research. BioRxiv. Citing STEM-CELLBANKER for GMP cryopreservation of Human Bronchial Organoids
2. Sano, E., Deguchi, S., Sakamoto, A., Mimura, N., Hirabayashi, A., Muramoto, Y., … & Takayama, K. (2021). Modeling SARS-CoV-2 infection and its individual differences with ACE2-expressing human iPS cells. Iscience, 24(5), 102428. Citing StemFit cell culture medium and iMatrix-511 as ECM
3. Serrano-Aroca, Á., Takayama, K., Tuñón-Molina, A., Seyran, M., Hassan, S. S., Choudhury, P. P., … & Brufsky, A. M. Carbon-Based Nanomaterials: Promising Antiviral Agents to Combat COVID-19 in the Microbial Resistant Era.